Veracyte logo

Veracyte

VCYT | NASDAQ
Chart Builder DCF Calculator
$24.01
-$0.32 (-1.32%)
At close: Nov 16, 2026, 4:00 PM ET
$23.50
-$0.51 (-2.12%)
After-hours: Nov 16, 2026, 7:46 PM ET
-1.32%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
80.9
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #18/1021 (Top 2%)

Key Statistics

Market Data

Market Cap $1.94B
1D Range
23.27 24.57
52W Range
23.27 60.49

Valuation (TTM)

PE 15.59
PB 1.35
EV/EBITDA 12.11

Valuation (NTM)

Forward PE 12.67
Forward PEG 1.01
Price Target $54.00
Loading financial charts...

Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Geno...

Sector Healthcare
Employees 755
IPO Date Oct 29, 2013
Fiscal Year January - December

Latest News

Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo

4 days ago · seekingalpha.com

Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript

6 days ago · seekingalpha.com

Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment

11 days ago · zacks.com

Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte

11 days ago · prnewswire.com

VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
What Veracyte (VCYT) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Veracyte (VCYT) Said on Its Q3 Earnings Call
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

12 days ago · zacks.com

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
Veracyte to Participate in Upcoming Investor Conferences

18 days ago · globenewswire.com

Veracyte to Participate in Upcoming Investor Conferences
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

20 days ago · zacks.com

Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

25 days ago · globenewswire.com

Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.51
Beat +24.33%
REV
$151.75M
Beat +3.14%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$54.00
Upside
+124.91%
Buy (6)
Hold (2)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.